Renal denervation in the antihypertensive arsenal - knowns and known unknowns

Area of Science:

• Cardiology
• Nephrology
• Hypertension Management

Background:

• Renal denervation (RDN) has been investigated for hypertension treatment for over a decade.
• Despite extensive research, its precise role in the antihypertensive therapeutic arsenal remains undefined.
• RDN demonstrates a clear blood pressure-lowering effect, comparable to a single antihypertensive medication, and possesses an excellent safety record.

Purpose of the Study:

• To evaluate the current standing and future prospects of renal denervation in managing hypertension.
• To address the clinical challenges in predicting patient response to RDN.
• To assess the long-term efficacy and outcome data for RDN therapy.

Main Methods:

• Review of clinical trial data, including recent studies like SPYRAL HTN-ON MED.
• Analysis of experimental research on post-RDN reinnervation.
• Evaluation of blood pressure as a surrogate endpoint versus hard clinical outcomes.

Main Results:

• RDN consistently lowers blood pressure (BP), but its efficacy is modest, akin to one antihypertensive drug.
• Predicting individual patient response to RDN remains clinically impossible.
• Long-term BP reduction efficacy is not yet convincingly established, with evidence of reinnervation post-procedure.
• Outcome data beyond BP reduction are lacking.

Conclusions:

• Renal denervation is a safe procedure that lowers blood pressure, but its clinical utility is limited by unpredictable patient response and insufficient long-term outcome data.
• Further research is needed to clarify patient selection criteria and long-term benefits.
• Potential candidates for RDN may include patients with resistant hypertension, sympathetic nervous system hyperactivity, or those seeking to minimize medication.